PXL01 program entering Phase III clinical trial

A biotech with global reach

Therapeutic peptides for bioactive wound care

Two first-in-category product candidates

New medical concept with extraordinary safety

Strategic partnerships in EU, Asia and USA

Innovative treatments for local administration

Press releases

November 23, 2018Promore Pharma AB (publ) Interim report January – September 2018
November 19, 2018Promore Pharma receives approval for Phase III study with PXL01 in India
November 9, 2018Nomination Committee Appointed for the Annual General Meeting 2019 in Promore Pharma
October 23, 2018Promore Pharma has had a successful meeting with the FDA regarding PXL01

More Press Releases

Interim report January – September 2018

Promore Pharma AB (publ) published its interim report for the third quarter 2018 on November 23, 2018.

Read the report

Calendar

January 7, 2019J.P. Morgan Annual Healthcare Conference 2019
February 26, 2019Year-end report 2018
May 21, 2019Interim report January – March 2019

More Events

Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides for the bioactive wound care market. The company’s aim is to develop two first-in-category products for indications with very few efficacious prescription pharmaceuticals, addressing high unmet medical need.

Vision

The vision of Promore Pharma is to solve the global medical problems of scarring, adhesions and chronic wounds.

Market

Within the global wound care market Promore Pharma’s product candidates are intended for the bioactive wound care segment. The bioactive wound care segment constitutes the fastest growing segment within the overall wound care market with a projected annual growth rate from 2015-2020 of 14 percent and is expected to reach USD 7.3 billion in 2020.